Sibrafiban
Sibrafiban (Ro 48-3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients suffering from acute coronary syndrome. The development of sibrafiban was terminated.
Link from a Wikipage to another Wikipage
primaryTopic
Sibrafiban
Sibrafiban (Ro 48-3657, proposed brand name Xubix) is the double prodrug of Ro-44-3888, which is a platelet aggregation inhibitor. It was being developed for secondary prevention of arterial thrombosis following unstable angina pectoris and acute myocardial infarction (MI). On August 6, 1999, Hoffmann-La Roche announced that the preliminary results from Phase III clinical trials had not shown that sibrafiban was better than aspirin in preventing recurrent ischemic events in patients suffering from acute coronary syndrome. The development of sibrafiban was terminated.
has abstract
Sibrafiban (Ro 48-3657, propos ...... of sibrafiban was terminated.
@en
CAS number
170094-62-9
ChEMBL
FDA UNII code
YUE443B0NF
KEGG
PubChem
Wikipage page ID
31,742,409
page length (characters) of wiki page
Wikipage revision ID
1,014,480,298
Link from a Wikipage to another Wikipage
CAS number
ChEMBL
ChemSpiderID
IUPAC name
[Z]--[​[1-[2-[​[4- ...... dinyl]oxyl]-acetic ethyl ester
@en
KEGG
D05834
@en
PubChem
SMILES
CCOCCOC1CCNC[C@H]NCc2cccCNO
@en
StdInChIKey
WBNUCLPUOSXSNJ-ZDUSSCGKSA-N
@en
UNII
YUE443B0NF
@en
wikiPageUsesTemplate
hypernym
comment
Sibrafiban (Ro 48-3657, propos ...... of sibrafiban was terminated.
@en
label
Sibrafiban
@en